Parent Board
Bonnie Dwyer, M.D., Executive Director, is a board-certified maternal-fetal medicine physician and founding member of the CAMK2 Therapeutics Network. She is a CAMK2 advocate and mother of Alexandra, who has a CAMK2B mutation, and Zachary, who is neurotypical. She lives in the San Francisco Bay Area with her husband, Ian Carroll, M.D., whose support has been vital to Alexandra’s well-being.
Neville Ross, a software engineer and founding member of the CAMK2 Therapeutics Network, lives in Dublin with his wife Christine, their child Caoimhe who has a CAMK2B mutation, and Shannon who is neurotypical, and played a key role in connecting with the ENCORE CAMK2 Center and organizing the first global CAMK2 gathering in 2019.
Matt Gibbs, a sales professional and founding member of the CAMK2 Therapeutics Network, lives in Massachusetts with his wife Pam, their daughter Lana who has a CAMK2B mutation, and son Tucker who is neurotypical, and has been advocating for Lana while building connections between families, researchers, and clinicians.
Sarah Pace lives in Texas with her husband Tom, daughter Emma who has a CAMK2B mutation, and daughter Hannah who is neurotypical, and as an engineer and dedicated advocate, she focuses on supporting children with CAMK2 disorders and strengthening the community through guidance and solutions.
Liat Vaknin-Nisan, a former lawyer and mediator turned caregiver and activist, lives near Tel Aviv, Israel, with her husband Tzadok, daughter Tahel who has a CAMK2B mutation, and son Ilay who is neurotypical, and has become a passionate advocate for families and children with special needs while actively participating in the CAMK2 parent board.
Staff
Dianne Mitchell, Ph.D., completed a fellowship at Harvard and has held leadership roles including Director of Genomics at Texas Tech University and Director of Operations at General Genetics Corporation; she is now Chief Operating Officer for CAMK2 Therapeutics Network and works as a consultant in biotech and pharmaceutical development.
Brad Bryan, Ph.D., M.B.A., completed a fellowship at Harvard Medical School and an MBA from the University of Massachusetts; he has served as a professor and executive in academia and medtech, and now works as the Director of Operations for CAMK2 Therapeutics Network and as a consultant in pharmaceuticals, patient advocacy, and business management.
Scientific Advisory Board
Dr. Howard Schulman, Ph.D., the “Father of CaMKII,” co-discovered its kinase activity with Nobel Laureate Paul Greengard and was a leading authority on CaMKII signaling in the brain, heart, and endocrine systems. He served as Professor and Chair of Neurobiology at Stanford University School of Medicine and co-founded a biotech company developing CaMKII inhibitors.
Dr. Danielle Veenma, M.D. is a clinical geneticist and physician–scientist at Erasmus Medical Center in Rotterdam whose work includes describing and interpreting CAMK2-related neurodevelopmental disorders through detailed patient phenotyping and genotype–phenotype correlation.
Dr. Geeske van Woerden, Ph.D. is a neuroscientist at Erasmus University Medical Center in Rotterdam—where she studies how disease-causing CAMK2 gene variants disrupt brain development and synaptic function.
Dr. Meg Stratton, Ph.D., is a professor at University of Massachuetts where she studies how CaMKII’s unique molecular properties enable synapse formation, maintenance, and long-term memory.
Dr. Kiki Chang, M.D., is a child, adolescent, and adult psychiatrist in private practice in Palo Alto and a former Stanford School of Medicine faculty member. He directed the Pediatric Bipolar Disorders Clinic and co-founded the PANS Clinic.
Florian Eichler, M.D., is a Professor of Neurology at Harvard Medical School and director of the Leukodystrophy Clinic at Massachusetts General Hospital. His research focuses on the genetics and metabolism of peroxisomal and white matter disorders.